|
Chỉ định và Liều dùng
Inhalation/Respiratory
Maintenance therapy in chronic obstructive pulmonary disease Adult: As metered-dose aerosol inhaler (2.5 mcg/actuation): 2 inhalations once daily.
|
|
Chống chỉ định
Monotherapy in the treatment of asthma. As primary treatment of asthma, acute episodes of bronchospasm, and acutely deteriorating COPD.
|
|
Thận trọng
Patient with CV disease (e.g. arrhythmia, coronary insufficiency, hypertension, heart failure), diabetes mellitus, hyperthyroidism, hypokalaemia, seizure disorder, aneurysm. Pregnancy and lactation.
|
|
Tác dụng không mong muốn
Significant: Hypersensitivity (e.g. angioedema), increased serum glucose, decreased serum K, CNS stimulation/excitation, thyroid activity stimulation; CV effects (e.g. increased pulse rate, and blood pressure, ECG changes), hypokalaemia, hyperglycaemia.
Infections and infestations: UTI. Musculoskeletal and connective tissue disorders: Arthralgia, back pain. Nervous system disorders: Dizziness. Respiratory, thoracic and mediastinal disorders: Nasopharyngitis, bronchitis. Skin and subcutaneous tissue disorders: Rash. Potentially Fatal: Paradoxical bronchospasm. |
|
Inhalation/Respiratory: C
|
|
Thông tin tư vấn bệnh nhân
This drug may cause dizziness, if affected, do not drive or operate machinery.
|
|
Chỉ số theo dõi
Monitor pulmonary function including FEV1 and FVC, blood pressure, heart rate, serum glucose and K levels; CNS stimulation.
|
|
Quá liều
Symptoms: Myocardial ischaemia, angina pectoris, hypertension or hypotension, tachycardia, arrhythmia, palpitation, dizziness, nervousness, insomnia, anxiety, headache, tremor, dry mouth, muscle spasm, nausea, fatigue, malaise, hypokalaemia, hyperglycaemia, metabolic acidosis. Management: Symptomatic and supportive treatment. May consider use of cardioselective β-blockers with extreme caution. Cardiac monitoring.
|
|
Tương tác
Increased risk of adverse CV effect with halogenated hydrocarbon anaesthetics. Increased risk of ventricular arrhythmia with drugs that prolong QT-interval (e.g. MAOIs, TCAs). Antagonistic effect with β-blockers. Increased risk of hypokalaemia with xanthine derivatives, corticosteroids, or non-K sparing diuretics. Increased plasma concentration with CYP enzyme inhibitor (e.g. ketoconazole).
Potentially Fatal: Additive sympathomimetic effect with other long-acting beta2-adrenergic agents. |
|
Tác dụng
Description:
Mechanism of Action: Olodaterol is a long acting beta2-receptor agonist. It stimulates intracellular adenyl cyclase, thereby increasing cyclic-3′, 5′-adenosine monophosphate (cAMP) levels, resulting in bronchodilation by relaxation of airway smooth muscle. Onset: 5 minutes. Duration: Approx 24 hours. Pharmacokinetics: Absorption: Rapidly absorbed systemically via lungs. Time to peak plasma concentration: 10-20 minutes. Absolute bioavailability: Approx 30%. Distribution: Volume of distribution: 1,110 L. Plasma protein binding: Approx 60%. Metabolism: Metabolised via direct glucuronidation by UGT2B7, UGT1A1, UGT1A7, and UGT1A9 and via O-demethylation primarily by CYP2C9 and CYP2C8; further metabolised via conjugation. Excretion: Via urine (5-7%, as unchanged drug). Elimination half-life: 7.5 hours. |
|
Đặc tính
 Source: National Center for Biotechnology Information. PubChem Database. Olodaterol, CID=11504295, https://pubchem.ncbi.nlm.nih.gov/compound/Olodaterol (accessed on Jan. 22, 2020) |
|
Bảo quản
Store at 25°C. Do not freeze.
|
|
Phân loại MIMS
|
|
Phân loại ATC
R03AC19 - olodaterol ; Belongs to the class of adrenergic inhalants, selective beta-2-adrenoreceptor agonists. Used in the treatment of obstructive airway diseases.
|
|
Tài liệu tham khảo
Anon. Olodaterol. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 07/02/2018. Buckingham R (ed). Olodaterol Hydrochloride. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 07/02/2018. Joint Formulary Committee. Olodaterol. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 07/02/2018. McEvoy GK, Snow EK, Miller J et al (eds). Olodaterol Hydrochloride. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 07/02/2018. Olodaterol. Drugs and Lactation Database (LactMed) [Internet]. Bethesda, MD. U.S. National Library of Medicine. https://www.ncbi.nlm.nih.gov/books/NBK501922/. Accessed 09/02/2018. Striverdi Respimat Inhalation Spray, Metered (Boehringer Ingelheim Pharmaceuticals, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 07/02/2018.
|
Đăng xuất
